FDA Smackdown: Cervarix vs. Gardasil

The FDA is rushing to rubber stamp Gardasil, a cervical cancer vaccine, for women ages 27-45.  Initially, the miracle HPV-preventer has been well received by its intended market—women and girls ages 9-26. Due to Gardasil’s success, amounting in $1.5 billion in sales last year, its makers, Merck & Co, are looking to expand potential beneficiaries. Merck has found Gardasil to be 91% effective in women 24-45 and are pushing for FDA approval within six months. The FDA is already reviewing a similarly effective British vaccine, Cervarix, put out by GlaxoSmithKline PLC, which is currently used for women up to 55 years of age in the U.K. No matter who wins the vaccine approval race, this is good news for women. With 250,000 reported deaths from cervical cancer every year, somethin’ has gotta be done! [ Boston Globe]